You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Engineered T Cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

Recruiting
  • B Cell Malignancies
  • Universal CD19-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

T-cell Lymphoma, T-cell Leukemia Trial in Indianapolis (CD4CAR)

Recruiting
  • T-cell Lymphoma
  • T-cell Leukemia
  • CD4CAR
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Dec 16, 2022

T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma Trial in Wuhan (Fludarabine +

Recruiting
  • T-Cell Lymphocytic Leukemia
  • +2 more
  • Fludarabine + Cyclophosphamide + CAR7-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Mar 1, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +11 more
  • Aldesleukin
  • +3 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 13, 2022

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

Triple Negative Breast Cancer Trial in Los Angeles (biological, procedure, drug)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Aldesleukin
  • +12 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Aug 9, 2023

Tumors Trial in United States (letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine)

Completed
Has Results
  • Neoplasms
  • letetresgene autoleucel (GSK3377794)
  • +2 more
  • Tampa, Florida
  • +5 more
Oct 31, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia, Refractory
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 3, 2023

COVID-19 Respiratory Infection Trial (PD-1 and ACE2 Knockout T Cells)

Not yet recruiting
  • COVID-19 Respiratory Infection
  • PD-1 and ACE2 Knockout T Cells
  • (no location specified)
Aug 13, 2021

HLA Typing and Tumor Neoantigen Identification forPhase I/II

Recruiting
  • Ovarian Cancer
  • +5 more
    • Houston, Texas
      MD Anderson Cancer Center
    Jul 27, 2022

    Hepatocellular Carcinoma Trial in Beijing, Shanghai, Shenyang (SCG101, PD1/PD-L1 checkpoint inhibitor)

    Recruiting
    • Hepatocellular Carcinoma
    • SCG101
    • PD1/PD-L1 checkpoint inhibitor
    • Beijing, China
    • +3 more
    May 7, 2022

    Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Wuhan (BTK inhibitor+ Fludarabine +

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • BTK inhibitor+ Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
    • Fludarabine + Cyclophosphamide + CAR-T-CD19 Cells
    • Wuhan, Hubei, China
      Union Hospital, Huazhong University of Science and Technology
    Oct 13, 2021

    Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing

    Recruiting
    • Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
    • Decitabine-primed Tandem CD19/CD20 CAR T Cells
    • Decitabine-primed Tandem CAR19/20 engineered T cells
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinese PLA General Hospital
    Mar 24, 2022

    Melanoma, Melanoma, Uveal, Head Neck Cancer Trial in Rotterdam (Adoptive therapy with autologous MC2 TCR T cells)

    Recruiting
    • Melanoma
    • +2 more
    • Adoptive therapy with autologous MC2 TCR T cells
    • Rotterdam, Netherlands
      Erasmus Medical Center
    Jun 1, 2022

    NSCLC, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma Trial in Duarte (Autologous, engineered T Cells targeting

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +5 more
    • Autologous, engineered T Cells targeting TP53 R175H
    • Duarte, California
      City of Hope
    May 17, 2023

    Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)

    Recruiting
    • Clear Cell Renal Cell Carcinoma
    • +4 more
    • CTX131
    • Nashville, Tennessee
      Research Site 1
    Mar 21, 2023

    Solid Tumors Trial in New York (procedure, drug, device, genetic)

    Active, not recruiting
    • Solid Tumors
    • Production of Genetically-modified T cells
    • +4 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Sep 1, 2022

    Solid Tumor Trial in United States (KITE-718, Cyclophosphamide, Fludarabine)

    Active, not recruiting
    • Solid Tumor
    • Gilbert, Arizona
    • +11 more
    Apr 5, 2022

    Prostate Cancer Trial in New York (engineered autologous T cells, cyclophosphamide)

    Active, not recruiting
    • Prostate Cancer
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Nov 28, 2022

    Head Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma Trial in Scottsdale, Chapel Hill (TSC-204-A0201, TSC-204-C0702,

    Not yet recruiting
    • Head and Neck Cancer
    • +20 more
    • TSC-204-A0201
    • +4 more
    • Scottsdale, Arizona
    • +1 more
    Aug 3, 2023